These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1606527)

  • 1. The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases.
    Leung DY
    Clin Rev Allergy; 1992; 10(1-2):93-104. PubMed ID: 1606527
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.
    Ronda N; Hurez V; Kazatchkine MD
    Vox Sang; 1993; 64(2):65-72. PubMed ID: 8456559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is intravenous administration of immunoglobulins a first-choice method in autoimmune diseases?].
    Vermeulen M
    Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1955-8. PubMed ID: 8413702
    [No Abstract]   [Full Text] [Related]  

  • 4. IVIG, aspirin, and Kawasaki disease.
    Morgan GJ; MacLeod C; Jenkins J; Stewart C; Craig B
    J Pediatr; 2003 Aug; 143(2):280-1; author reply 281. PubMed ID: 12970651
    [No Abstract]   [Full Text] [Related]  

  • 5. Kawasaki disease and human parvovirus B19 antibody: role of immunoglobulin therapy.
    Fukushige J; Takahashi N; Ueda K; Okada K; Miyazaki C; Maeda Y
    Acta Paediatr Jpn; 1995 Dec; 37(6):758-60. PubMed ID: 8775567
    [No Abstract]   [Full Text] [Related]  

  • 6. Adult Kawasaki disease: evaluating the fluctuation of circulating lymphocytes associated with i.v. immunoglobulin treatment.
    Fujimoto N; Teramura K; Tanaka T
    J Dermatol; 2012 Nov; 39(11):957-8. PubMed ID: 22390144
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
    Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
    Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
    Khan S; Doré PC; Sewell WA
    Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
    [No Abstract]   [Full Text] [Related]  

  • 9. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I; Marino A; Simonini G; Cimaz R
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract]   [Full Text] [Related]  

  • 10. The clinical efficacy of IVGG in Kawasaki disease.
    Rowley AH; Shulman ST
    Clin Rev Allergy; 1992; 10(1-2):81-91. PubMed ID: 1606526
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
    Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S
    Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kawasaki disease--treatment with intravenous immunoglobulin during the acute stage.
    Singh S; Kumar L
    Indian Pediatr; 1996 Aug; 33(8):689-92. PubMed ID: 8979554
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease.
    Lee HK; Kim DS; Noh GW; Lee KY
    Yonsei Med J; 1996 Oct; 37(5):357-63. PubMed ID: 8997168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous immunoglobulin on inhibiting peripheral blood lymphocyte apoptosis in acute Kawasaki disease.
    Yi QJ; Li CR; Yang XQ
    Acta Paediatr; 2001 Jun; 90(6):623-7. PubMed ID: 11440093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Present situation and new challenges for medical treatment of Kawasaki disease].
    Ikeda K; Hamaoka K
    Nihon Rinsho; 2014 Sep; 72(9):1523-9. PubMed ID: 25518397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major methylation alterations on the CpG markers of inflammatory immune associated genes after IVIG treatment in Kawasaki disease.
    Li SC; Chan WC; Huang YH; Guo MM; Yu HR; Huang FC; Kuo HC; Kuo HC
    BMC Med Genomics; 2016 Aug; 9 Suppl 1(Suppl 1):37. PubMed ID: 27534746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between T-cell HLA-DR expression and intravenous immunoglobulin treatment response in Kawasaki disease.
    Wakiguchi H; Hasegawa S; Suzuki Y; Kudo K; Ichiyama T
    Pediatr Res; 2015 Apr; 77(4):536-40. PubMed ID: 25580740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.
    Gupta M; Noel GJ; Schaefer M; Friedman D; Bussel J; Johann-Liang R
    J Clin Immunol; 2001 May; 21(3):193-9. PubMed ID: 11403226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.
    Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC
    Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VI nerve palsy after intravenous immunoglobulin in Kawasaki disease.
    Rodríguez-Lozano A; Juárez-Echenique JC; Rivas-Larrauri F; Gámez-González LB; Yamazaki-Nakashimada M
    Allergol Immunopathol (Madr); 2014; 42(1):82-3. PubMed ID: 23340202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.